A registered PHASE3 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase 3
- Study design
- RANDOMIZED · PARALLEL · TREATMENT · DOUBLE
- Evidence population
- Human clinical study registration
- Participants
- 1775
- Population
- ALL · 50 Years
- Duration
- 2014-12-08 to 2018-03-28
- Intervention
- Brolucizumab ophthalmic solution; Aflibercept ophthalmic solution
- Comparator
- Aflibercept 2 mg
- Outcomes measured
- Change From Baseline in Best Corrected Visual Acuity (BCVA) (Letters Read) at Week 48 - Study Eye — Baseline, Week 48; Average Change From Baseline in BCVA (Letters Read) Over the Period Week 36 Through Week 48 - Study Eye — Baseline, Wee…; Proportion of Subjects With Positive q12 (Every 12 Weeks) Treatment Status at Week 48 — Weeks 16, 20, 28, 32, 40, 44, 48; Proportion of Subjects With Positive q12 Treatment Status at Week 48 Within the Subjects With no q8 (Every 8 Weeks) Tre…; Proportion of Subjects With Positive q12 Treatment Status up to Week 96 — Weeks 16, 20, 28, 32, 40, 44, 52, 56, 64, 68,…; Proportion of Subjects With Positive q12 Treatment Status at Week 96 Within the Subjects With no q8 Treatment Need Duri…; Change From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye — Baseline, Weeks 4, 8, 12, 16, 20,…; Average Change From Baseline in BCVA (Letters Read) Over the Period Week 4 to Week 48/96 - Study Eye — Baseline, Weeks…; Average Change From Baseline in BCVA (Letters Read) Over the Period Week 12 to Week 48/96 - Study Eye — Baseline, Weeks…; Average Change From Baseline in BCVA (Letters Read) Over the Period Week 84 to Week 96 - Study Eye — Baseline, Weeks 84…; Percentage of Subjects With >=15 Letter Gain From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study E…; Percentage of Subjects With >=10 Letter Gain From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study E…; Percentage of Subjects With >=5 Letter Gain From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Ey…; Percentage of Subjects With >=15 Letter Loss From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study E…; Percentage of Subjects With >=10 Letter Loss From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study E…; Percentage of Subjects With >=5 Letter Loss From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Ey…; Percentage of Subjects With BCVA of 73 Letters Read or More at Each Visit - Study Eye — Baseline, Weeks 4, 8, 12, 16, 2…; Change From Baseline in Central Subfield Thickness (CSFTtot) at Each Post-baseline Visit - Study Eye — Baseline, Weeks…; Average Change From Baseline in CSFTtot Over the Period Week 36 Through Week 48 - Study Eye — Baseline, Weeks 36, 40, 4…; Average Change From Baseline in CSFTtot Over the Period Week 84 Through Week 96 - Study Eye — Baseline, Weeks 84, 88, 9…
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 100% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Vision ageing · 100%Abstract contains controlled term: age-related macular degeneration. Source terminology contains: age-related macular degeneration. Abstract supplies longevity context: age-related. Study type is explicitly identified as INTERVENTIONAL.
Automated source check 100% · update recency 65%. These figures help sort records; they are not medical ratings.